Fig. 4

Characterization of kdelr3-deficient human and zebrafish. a SS-OCT images of right (OD) and left (OS) eyes for individuals with and without rare PTVs in KDLER3. b Quantification of eye measurement, retinal and choroidal thickness in normal eyes and EM eyes with KDELR3-deficient. P-value calculated by two-sided Wilcoxon rank sum test. c Quantification of eye axis length, the axis-to-body length ratio, lens diameter, and lens-to-body length ratio across various MO dose groups. Each group has more than five eyeballs. Data was analyzed by two-sided Student’s t-test, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 significantly different from control 0.5 ng group (n.s. non-significant differences). Boxplots display the median, quartiles, and variability of the data. d Immunohistochemistry of control-MO injected eyes and kdelr3-deficient morphants. e, Boxplots representing the normalized fluorescence intensity associated with various MO dose groups. Each group has more than ten eyeballs. Data was analyzed by two-sided Student’s t-test, *P < 0.05, **P < 0.01, ***P < 0.001 significantly different from control group (n.s. non-significant differences). Boxplots display the median, quartiles, and variability of the data. f VMR testing in kdelr3-deficient zebrafish morphants. Larvae injected with kdelr3-MO (0.35 ng) showed a weaker ON response and a significantly attenuated OFF response compared to control larvae. g The data in the Figure represent averages ± standard deviation of triplicate assays in one experiment. **P < 0.01, ***P < 0.001 (two-sided Student’s t-test).